Tag: Ipsen

MHRA Approved Dysport for Upper Limb Spasticity in Children with Cerebral Palsy Treatment

Biopharmaceutical company Ipsen has secured approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its Dysport as a symptomatic treatment for upper limb spasticity in ch...

Ipsen Added BLU-782 to Rare Diseases Pipeline for $535m

fake drugs
Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossificans progressiv...

Ipsen and Blueprint Medicines Agreed for Cooperation in BLU-782 Development

Ipsen and Blueprint Medicines Corporation announced Ipsen, through its subsidiary Clementia Pharmaceuticals, and Blueprint Medicines have entered into an exclusive, worldwide license agreement for the...

FDA Expanded Use of Dysport® for Upper Limb Spasticity Treatment

Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced that the United States Food and Drug Administration (FDA) has expanded the use of Dysport® (abobotulinumtoxinA) for injection to include the ...

Ipsen Registered New Cancer Drug in Russia

Ipsen announced the registration of a new cancer drug in Russia, cabosantinib. The drug is intended for the treatment of advanced renal cell carcinoma (RCC) in adult patients with intermediate or poor...

Ipsen Registered New Anticancer Drug in Russia

Ipsen announced the registration of a new anticancer drug in Russia, cabosantinib. The drug is intended for the treatment of advanced renal cell carcinoma (RCC) in adult patients with intermediate or ...

Ipsen Buys Rare Disease Company

Ipsen and Clementia Pharmaceuticals today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset palovarotene, a...

Ipsen Warns about Brexit Influence on Pharma

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines. As Theresa May attempts to drum up support for her B...

Ipsen becomes a member of Biotechnology Innovation Organization

biotech
Ipsen announced it has joined the Biotechnology Innovation Organization (BIO), the largest association of biotechnology companies, academic institutions and biotech centers.

Ipsen partnered with MD Anderson Cancer Center to develop new cancer drug

cancer treatment
Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate.

Arix Bioscience and Ipsen start cooperation on innovative therapies

microscope
Arix Bioscience, a global healthcare and life science company, and Ipsen, a global specialty-driven biopharmaceutical company announced a strategic agreement to develop and commercialise innovative therapies.